Poikiloderma (a skin condition involving hypopigmentation, hyperpigmentation, spider veins and atrophy) with neutropenia (PN) is a unique clinical presentation that can be caused by mutations in the U6 snRNA biogenesis phosphodiesterase 1 gene (USB1). Curiously enough, the USB1 protein is required for U6 snRNA synthesis in yeast and zebrafish, but not humans.
Chemocentryx Inc. has described aryl sulfonyl (hydroxy) piperidines acting as C-C chemokine receptor type 6 (CCR6) antagonists reported to be useful for the treatment of atopic dermatitis, psoriasis, endometriosis, periodontitis, rheumatoid arthritis, scleroderma, psoriatic arthritis and inflammatory disorders.
Protagonist Therapeutics Inc. got a win in its phase IIb study and is making plans for a phase III. JNJ-2113 (formerly PN-235), an oral, interleukin-23 receptor antagonist peptide, hit its primary efficacy endpoint in treating moderate to severe plaque psoriasis. A statistically significant greater proportion of the participants receiving JNJ-2113 saw a 75% improvement in their skin lesions compared to placebo at week 16.
Atopic dermatitis (AD) is an inflammatory skin disease with complex pathogenesis. Researchers from the Swiss Institute of Allergy and Asthma Research and their collaborators have investigated biomarkers tied to AD and its severity.
Once-monthly subcutaneous injections of CSL Ltd.’s CSL-312 (garadacimab) significantly reduced the rate of hereditary angioedema (HAE) attacks compared to placebo, meeting both primary and secondary endpoints in the pivotal phase III Vanguard trial. Based on the trial results, CSL will file global regulatory submissions later in 2023. Based on the trial results, CSL will file global regulatory submissions later in 2023. A humanized anti-factor XIIa monoclonal antibody, garadacimab is self-administered by subcutaneous administration once monthly, which is a huge convenience for patients, Andrew Nash, CSL’s chief scientific officer and senior vice president for research, told BioWorld.
Once-monthly subcutaneous injections of CSL Ltd.’s CSL-312 (garadacimab) significantly reduced the rate of hereditary angioedema (HAE) attacks compared to placebo, meeting both primary and secondary endpoints in the pivotal phase III Vanguard trial. Based on the trial results, CSL will file global regulatory submissions later in 2023.
Environmental factors, such as those from food allergens, can modulate IgE-driven hypersensitivity related to the genetics of allergy. Researchers from the Korea National Institute of Health aimed to investigate the impact of polymorphisms in the SORBS1 gene in relation to atopic dermatitis based on milk exposure.
Biocryst Pharmaceuticals Inc.’s unveiling of real-world data Feb. 24 with its approved Orladeyo (berotralstat) for prophylactic treatment of hereditary angioedema (HAE) brought more attention to the space, due to yield findings from would-be competitors in the near term.